Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab

Journal of the American College of Cardiology

Volumn 63, Issue 23, 2014, Pages 2541-2548

  Stroes, Erik ^a   Colquhoun, David ^b   Sullivan, David ^c   Civeira, Fernando ^d   Rosenson, Robert S ^e   Watts, Gerald F ^f   Bruckert, Eric ^g   Cho, Leslie ^h   Dent, Ricardo ⁱ   Knusel, Beat ⁱ   Xue, Allen ⁱ   Scott, Rob ⁱ   Wasserman, Scott M ⁱ   Rocco, Michael ^h  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Wesley Medical Centre   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

evolocumab; ezetimibe; hypercholesterolemia; LDL cholesterol; statin intolerance

Indexed keywords

CHOLESTEROL; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9; SERINE PROTEINASE; SUBTILISIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MUSCLE DISEASE; MYALGIA; MYOSITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG TOLERANCE; FEMALE; FOLLOW UP; IMMUNOLOGY; MALE; MULTICENTER STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; APOPTOSIS; CHOLESTEROL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902157271     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.03.019     Document Type: Article

References (22)

1. C. Baigent, A. Keech, and P.M. Kearney et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. Cholesterol Treatment Trialists' (CTT) Collaboration, C. Baigent, and L. Blackwell et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. H. Zhang, J. Plutzky, and S. Skentzos et al. Discontinuation of statins in routine care settings: a cohort study Ann Intern Med 158 2013 526 534
4. Y.H. Gomez Sandoval, M.V. Braganza, and S.S. Daskalopoulou Statin discontinuation in high-risk patients: a systematic review of the evidence Curr Pharm Des 17 2011 3669 3689
5. M.E. Visser, G. Wagener, and B.F. Baker et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial Eur Heart J 33 2012 1142 1149
6. M. Cuchel, E.A. Meagher, and H. du Toit Theron et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46
7. M. Abifadel, M. Varret, and J.P. Rabès et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
8. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
9. J.D. Horton, J.C. Cohen, and H.H. Hobbs Molecular biology of PCSK9: its role in LDL metabolism Trends Biochem Sci 32 2007 71 77
10. D. Sullivan, A.G. Olsson, and R. Scott et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
11. L. Cho, M. Rocco, and D. Colquhoun et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled Phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy Clin Cardiol 37 2014 131 139
12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
13. M.J. Koren, P. Lundqvist, M. Bolognese for the MENDEL-2 Investigators Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab J Am Coll Cardiol 63 2014 2531 2540
14. T.R. Pedersen, J. Kjekshus, and K. Berg et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994 Atheroscler Suppl 5 2004 81 87
15. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 2013 Nov 7 [E-pub ahead of print].
16. R.H. Knopp, C.A. Dujovne, and A. Le Beaut et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies Int J Clin Pract 57 2003 363 368
17. R.M. Califf, Y. Lokhnygina, and C.P. Cannon et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 2010 705 709
18. N.R. Desai, P. Kohli, and R.P. Giugliano et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial Circulation 128 2013 962 969
19. F. Raal, R. Scott, and R. Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
20. E.A. Stein, S. Mellis, and G.D. Yancopoulos et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
21. A.L. Mammen, T. Chung, and L. Christopher-Stine et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy Arthritis Rheum 63 2011 713 721
22. Search Collaborative Group, E. Link, and S. Parish et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study N Engl J Med 359 2008 789 799